Nico Orgo Biotech Profile
Key Indicators
- Authorised Capital ₹ 2.00 M
as on 24-10-2024
- Paid Up Capital ₹ 0.10 M
as on 24-10-2024
- Company Age 13 Year, 11 Months
- Last Filing with ROC 31 Mar 2024
- Satisfied Charges ₹ 1.12 Cr
as on 24-10-2024
- Revenue 125.35%
(FY 2023)
- Profit -131.94%
(FY 2023)
- Ebitda -169.43%
(FY 2023)
- Net Worth -6.75%
(FY 2023)
- Total Assets -48.62%
(FY 2023)
About Nico Orgo Biotech
The Company is engaged in the Agriculture Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 2.00 M and a paid-up capital of Rs 0.10 M.
The company has closed loans amounting to ₹1.12 Cr, and has no open charges as per Ministry of Corporate Affairs (MCA) records.
Kartik Laijawala and Karan Virji serve as directors at the Company.
- CIN/LLPIN
U01403GJ2011PTC064045
- Company No.
064045
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
17 Feb 2011
- Date of AGM
18 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Ahmedabad
Industry
Company Details
- Location
Kheda, Gujarat, India
- Telephone
- Email Address
- Website
- Social Media-
Who are the key members and board of directors at Nico Orgo Biotech?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Kartik Laijawala  | Director | 17-Feb-2011 | Current |
| Karan Virji | Director | 17-Feb-2011 | Current |
Financial Performance of Nico Orgo Biotech.
Nico Orgo Biotech Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 125.35% increase. The company also saw a substantial fall in profitability, with a 131.94% decrease in profit. The company's net worth dipped by a decrease of 6.75%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations | |||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Nico Orgo Biotech?
In 2023, Nico Orgo Biotech had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Nico Orgo Marketing Private LimitedActive 26 years 10 monthsKartik Laijawala and Karan Virji are mutual person
Nta Pharma Private LimitedActive 12 years 6 monthsKartik Laijawala and Karan Virji are mutual person
Charges (Loans)
₹0
₹11.21 M
Charges Breakdown by Lending Institutions
- Indian Bank : 0.99 Cr
- Hdfc Bank Limited : 0.13 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 29 Jan 2016 | Indian Bank | ₹9.87 M | Satisfied |
| 26 Mar 2012 | Hdfc Bank Limited | ₹1.34 M | Satisfied |
How Many Employees Work at Nico Orgo Biotech?
Unlock and access historical data on people associated with Nico Orgo Biotech, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Nico Orgo Biotech, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Nico Orgo Biotech's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.